Corazon Sanders
Director/Board Member bei MOLECULAR TEMPLATES, INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| John Oyler | M | 56 | 14 Jahre | |
| Eric Poma | M | 52 | 24 Jahre | |
| Jason Kim | M | 49 | 14 Jahre | |
| Emil Kakkis | M | 63 | 14 Jahre | |
| Fang Liang Zhang | M | 59 | 8 Jahre | |
| Gabriela Gruia | M | 67 | 2 Jahre | |
| Julia Wang | F | 53 | 4 Jahre | |
| Leewen Lin | M | - |
AbGenomics International, Inc.
 AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Xiao Dong Wang | M | 61 | 14 Jahre | |
| Ying Huang | M | 51 | 5 Jahre | |
| Lori Macomber | F | 53 | 5 Jahre | |
| Patrick Yang | M | 75 |
Altrubio, Inc.
 Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | 3 Jahre |
| Judy Chou | M | 58 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
| Daniel Welch | M | 66 | 9 Jahre | |
| Wai Man Yau | M | 48 | 4 Jahre | |
| Shehnaaz Suliman | M | 52 | 5 Jahre | |
| Alessandro Riva | M | 63 | 2 Jahre | |
| Xiao Bin Wu | M | 62 | 6 Jahre | |
| Crystal Chen | F | - | 3 Jahre | |
| Patrick J. Casey | M | 68 | 4 Jahre | |
| Anthony Hooper | M | 69 | 4 Jahre | |
| Tomas Jan Heyman | M | 68 | 2 Jahre | |
| Kristen Quigley | F | 53 | 7 Jahre | |
| Ranjeev Krishana | M | 50 | 10 Jahre | |
| Donald Glazer | M | 79 | 11 Jahre | |
| Ye Wang | F | 55 | 9 Jahre | |
| Eric Crombez | M | - | 7 Jahre | |
| Qing Qing Yi | M | 52 | 10 Jahre | |
| Wendy Yan | F | 58 | 10 Jahre | |
| Lai Wang | M | 47 | 13 Jahre | |
| Deborah Dunsire | M | 61 | 7 Jahre | |
| Margaret Dugan | M | 67 | 2 Jahre | |
| Amrit Ray | M | 51 | 2 Jahre | |
| Michael Goller | M | 49 | 9 Jahre | |
| Harold Selick | M | 69 | 7 Jahre | |
| David Hoffmann | M | 79 | 7 Jahre | |
| Kevin Lalande | M | 51 | 15 Jahre | |
| Matthew Fust | M | 59 | 10 Jahre | |
| Li Mao | M | 67 | 2 Jahre | |
| Olivier Brandicourt | M | 68 | - | |
| Xiao Hui Ji | M | 62 | 4 Jahre | |
| Michael Narachi | M | 64 | 9 Jahre | |
| Scott Samuels | M | 54 | - | |
| Shih-Yao Lin | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Ruth C. S. Li | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Liz Gosen | F | - | 5 Jahre | |
| Chan Lee | M | - | 2 Jahre | |
| Graham Hardiman | M | - | 3 Jahre | |
| Yuhong Qiu | M | - | 6 Jahre | |
| Joshua Higa | M | - | - | |
| Guowei Fang | M | - | 2 Jahre | |
| Yan Liu | M | - | 5 Jahre | |
| Eva Yin | F | - | - | |
| Tracy Luo | M | - | 6 Jahre | |
| Clare Fisher | F | 51 | 3 Jahre | |
| Samuel Wadsworth | M | 75 | 7 Jahre | |
| Ernie Meyer | M | 60 | 4 Jahre | |
| Yung-Hua Chung | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Stephen G. Juelsgaard | M | 75 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
| John C. Doyle | M | 55 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | - |
| Steven J. Gavel | M | - | 6 Jahre | |
| John Pinion | M | 58 | 9 Jahre | |
| Thomas Kassberg | M | 63 | 13 Jahre | |
| Jason W. Radford | M | 42 | 4 Jahre | |
| Be-Sheng Kuo | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Hazel T. Y. Cheng | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Erik Harris | M | 54 | 7 Jahre | |
| Liza Heapes | F | - | - | |
| Howard Horn | M | 47 | 1 Jahre | |
| Vimal Srivastava | M | 58 | 13 Jahre | |
| Sean Bohen | M | 58 |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | 5 Jahre |
| Theodore Huizenga | M | 53 | 10 Jahre | |
| Dennis Huang | M | 59 | 9 Jahre | |
| Karah Parschauer | F | 46 | 8 Jahre | |
| Chia-Jung Yang | F | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Jessie Yeung | F | - | 5 Jahre | |
| Guillaume Vignon | M | - | 6 Jahre | |
| Elaine Qian | F | - | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Adam Daniel Cutler | M | 50 | 4 Jahre | |
| Robert Nelsen | M | 60 | 5 Jahre | |
| Howard H. Pien | M | 66 | 4 Jahre | |
| Maggie Wilderotter | F | 69 | 4 Jahre | |
| Bill Aliski | M | 75 | 11 Jahre | |
| Yong Ben | M | 50 | 3 Jahre | |
| Jonathan Lanfear | M | 55 | 6 Jahre | |
| Danielle Keatley | F | - | 5 Jahre | |
| Scott Morenstein | M | 48 | 6 Jahre | |
| Yung Cheng Chen | M | 67 | 6 Jahre | |
| Thomas Daniel | M | 69 | 3 Jahre | |
| Hal Barron | M | 62 | 4 Jahre | |
| Lars Ekman | M | 74 | 7 Jahre | |
| sam Su | M | 71 | 4 Jahre | |
| Richard Klausner | M | 72 | 5 Jahre | |
| David Hirsch | M | 53 | 6 Jahre | |
| Thomas Malley | M | 55 | 8 Jahre | |
| Anthony Evnin | M | 83 | 4 Jahre | |
| Sean McLennan | M | 54 | 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 53 | 54,64% |
| Cayman Islands | 44 | 45,36% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Corazon Sanders
- Persönliches Netzwerk
